Pan-cancer clinical impact of latent drivers from double mutations
Open Access
- 20 February 2023
- journal article
- research article
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-14
Abstract
Here, we discover potential ‘latent driver’ mutations in cancer genomes. Latent drivers have low frequencies and minor observable translational potential. As such, to date they have escaped identification. Their discovery is important, since when paired in cis, latent driver mutations can drive cancer. Our comprehensive statistical analysis of the pan-cancer mutation profiles of ~60,000 tumor sequences from the TCGA and AACR-GENIE cohorts identifies significantly co-occurring potential latent drivers. We observe 155 same gene double mutations of which 140 individual components are cataloged as latent drivers. Evaluation of cell lines and patient-derived xenograft response data to drug treatment indicate that in certain genes double mutations may have a prominent role in increasing oncogenic activity, hence obtaining a better drug response, as in PIK3CA. Taken together, our comprehensive analyses indicate that same-gene double mutations are exceedingly rare phenomena but are a signature for some cancer types, e.g., breast, and lung cancers. The relative rarity of doublets can be explained by the likelihood of strong signals resulting in oncogene-induced senescence, and by doublets consisting of non-identical single residue components populating the background mutational load, thus not identified.Keywords
This publication has 76 references indexed in Scilit:
- Impact of deleterious passenger mutations on cancer progressionProceedings of the National Academy of Sciences, 2013
- Self-Adaptive Image Reconstruction Inspired by Insect Compound Eye MechanismComputational and Mathematical Methods in Medicine, 2012
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cellsNucleic Acids Research, 2012
- Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α ( PIK3CA )Proceedings of the National Academy of Sciences, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Distinct requirement for an intact dimer interface in wild‐type, V600E and kinase‐dead B‐Raf signallingThe EMBO Journal, 2012
- Analyzing Effects of Naturally Occurring Missense MutationsComputational and Mathematical Methods in Medicine, 2012
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature, 2011
- Accumulation of driver and passenger mutations during tumor progressionProceedings of the National Academy of Sciences, 2010
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008